Introduction
SHP-2 is a cytoplasmic protein tyrosine phosphatase (PTP) that plays a crucial role in signal transduction downstream of growth factor/cytokine receptors to regulate cellular responses, including proliferation, morphogenesis and cell motility (Neel et al., 2003) . Biochemical and genetic evidence places SHP-2 upstream of RAS, and SHP-2 is required for full activation of RAS-extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase signaling pathway. Depending on the receptor or cell type, SHP-2 can enhance or suppress other RAS-effector pathways such as the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. However, the key substrates that must be dephosphorylated in SHP-2-mediated signaling remain unclear.
Germline missense mutations in the PTPN11 gene, which encodes SHP-2, account for about half of the cases of Noonan syndrome, an autosomal dominant developmental disorder (Tartaglia et al., 2001) . PTPN11 mutations are also observed in about 90% of cases of a Noonan-like syndrome called LEOPARD syndrome (Digilio et al., 2002) . Phenotypically overlapping Costelo syndrome and cardio-facio-cutaneous syndrome are caused by gain-of-function HRAS mutation and KRAS/BRAF/MEK1/MEK2 mutation, respectively (Aoki et al., 2005; Niihori et al., 2006; RodriguezViciana et al., 2006) . Some Noonan syndrome cases are also attributed to gain-of-function mutations in SOS1 that encodes the RAS guanine nucleotide exchange factor or KRAS (Schubbert et al., 2006; Roberts et al., 2007; Tartaglia et al., 2007) . The observations collectively indicate that aberrant activation of the SHP-2-RAS-ERK pathway plays a key role in these overlapping developmental disorders (Gelb and Tartaglia, 2006) . Noonan syndrome is also associated with increased risk of juvenile myelomonocytic leukemia (JMML) (Choong et al., 1999) , suggesting the role of mutant SHP-2 in leukemogenesis. Indeed, somatic mutations in PTPN11 occur in 35% cases of JMML, 4% of childhood acute myelocytic leukemias and 7% of childhood B-cell acute lymphoblastic leukemias (Tartaglia et al., 2003 (Tartaglia et al., , 2004 Loh et al., 2004) .
SHP-2 has two tandemly arranged SH-2 domains, N-SH2 and C-SH2, at the N-terminal half, a catalytic PTP domain, and a C-terminal region. In the basal state, SHP-2 is maintained in an inactive conformation by hydrophobic interaction between the N-SH2 domain and the PTP domain. Binding of a phosphotyrosinecontaining peptide to the N-SH2 domain alleviates the autoinhibition to form an open conformation with active phosphatase activity (Hof et al., 1998; Neel et al., 2003) . Most if not all mutations found in Noonan syndrome or leukemia affect residues in the N-SH2 domain or PTP domain that abolish the autoinhibitory interaction and thereby exhibit increased basal phosphatase activity (Tartaglia et al., 2003) . Hence, SHP-2 is a bona fide oncoprotein, gain-of-function mutation of which is involved in leukemogenesis.
Given the crucial role of RAS activation in tumorigenesis, deregulated SHP-2, which aberrantly activates the RAS-dependent signaling, is considered to have a more general contribution in neoplasms. However, previous studies showed that PTPN11 mutations are rare in non-hematological human malignancies (Bentires-Alj et al., 2004; Martinelli et al., 2006) . In this work, we investigated PTPN11 mutation in primary human solid tumors and found a mutant PTPN11 allele that encodes an SHP-2 with threonine-507 to lysine (T507K) substitution in a case of hepatocellular carcinoma. In contrast to wild type, Noonan-associated or leukemia-specific SHP-2, the newly isolated T507K SHP-2 mutant had altered substrate specificity and exhibited oncogenic RAS-like transforming activity both in vivo and in vitro.
Results
Mutation analysis of PTPN11 in primary human solid tumors Genomic DNAs were obtained from surgically resected liver cancers (n ¼ 72), stomach cancers (diffuse-type adenocarcinoma, n ¼ 108) and thyroid tumors (n ¼ 54) (Table 1) . Isolated DNAs were subjected to PCR-singlestrand conformation polymorphism (SSCP) analysis and direct nucleotide sequencing analysis to identify PTPN11 mutations. Mutations in exons 3 and 13 of PTPN11 were screened because these two exons are mutation hot spots. The screening revealed a 1520C>A mutation, resulting in a T507K substitution in the PTP domain of SHP-2, in a hepatocellular carcinoma sample (Figures 1a and b) . The corresponding normal DNA from the same patient did not have this nucleotide change (Figure 1b) , indicating that the mutation is of somatic origin. Hence, in this study, the estimated mutation frequencies of PTPN11 were 0.4 and 1.4% in all samples and liver cancers, respectively. The identified T507K mutation has been reported in a de novo neuroblastoma and a de novo childhood acute myelocytic leukemia (Bentires-Alj et al., 2004; Tartaglia et al., 2004) but not in Noonan syndrome or JMML.
Threonine-507 (T507) of SHP-2 is highly conserved among PTPs (Andersen et al., 2001) and constitutes the surface of the catalytic cleft in the PTP domain, facing the N-SH2 domain in the basal state of SHP-2 (Hof et al., 1998) (Figures 1c and d) . The lysine substitution may inhibit the autoinhibitory interaction between the N-SH2 domain and PTP domain, thereby activating the basal phosphatase activity. In addition, T507 constitutes the QTXXQYXF 'catalytic water motif', which is involved in the dephosphorylation reaction by forming a hydrogen bond with the PTP signature motif. The structural information raises the possibility that T507K mutation affects the enzymatic activity of SHP-2.
Tyrosine phosphatase activity of T507K SHP-2 To investigate the effect of T507K mutation on SHP-2 activity, wild type or mutant SHP-2 was made as a recombinant protein in Escherichia coli ( Figure 2a ) and an in vitro phosphatase assay was performed using paranitrophenyl phosphate (pNPP) as a substrate. In this phosphatase assay, the E76K mutant of SHP-2, the most common leukemia-specific mutant that causes complete relief of autoinhibition and full activation (Neel et al., 2003; Keilhack et al., 2005; Tartaglia et al., 2006) , exhibited more than 100-fold activity of wild-type SHP-2. In contrast, the T507K mutant showed only twofold increase in phosphatase activity compared with that of wild-type SHP-2 ( Figure 2b ). Introduction of the E76K mutation into the T507K SHP-2 increased the phosphatase activity to the level of E76K SHP-2, indicating that T507K mutation does not affect the magnitude of the fully activated SHP-2 phosphatase activity ( Figure 2b ). Thus, T507K mutation slightly impairs the autoinhibitory interaction and thereby causes marginal but significant increase in the basal phosphatase activity.
Effect of T507K mutation on the substrate specificity of SHP-2 An in vivo substrate-trapping assay of SHP-2 was next performed to evaluate changes in substrate specificity caused by the T507K mutation. To this end, DM/ T507K SHP-2-Myc was made by introducing T507K substitution into a substrate-trapping mutant of DM SHP-2-Myc (Agazie and Hayman, 2003) , which forms stable enzyme-substrate complexes that could be detected through immunoprecipitation. Substrate-trapping activity of DM/T507K SHP-2-Myc was confirmed (Figure 3a) . As a control, E76K mutation was also introduced into DM SHP-2-Myc to make DM/E76K SHP-2-Myc. DM SHP-2-Myc, DM/E76K SHP-2-Myc or DM/T507K SHP-2-Myc was expressed in AGS human gastric epithelial cells. Anti-Myc immunoprecipitates of the AGS cell lysates were immunoblotted with an anti-phosphotyrosine antibody. The results of the substrate-trapping experiment revealed that DM/T507K SHP-2-Myc specifically coprecipitated several tyrosinephosphorylated proteins with molecular masses of approximately 65 000B70 000 Da, which were not coprecipitated with DM SHP-2-Myc or DM/E76K SHP-2-Myc ( Figure 3b , lanes 5-7). We also note that the substrate specificity of DM/E76K SHP-2-Myc did not differ from that of DM SHP-2-Myc, indicating that E76K is a hypermorphic but not neomorphic SHP-2 mutation as has been suggested (Keilhack et al., 2005) ( Figure 3b ). From these results, we concluded that T507K SHP-2 exhibits altered substrate specificity either through acquisition of new substrates or significant alterations in its interaction with particular substrates.
Transformation of NIH3T3 cells by T507K SHP-2
The above-described observations indicated that T507K mutation causes both quantitative and qualitative changes in SHP-2 as a phosphatase. Since T507K mutation was found in solid tumors, we next investigated the transforming potential of T507K SHP-2 by using the NIH3T3 focus-formation assay, which preferentially detects deregulated RAS-ERK signaling (Clark et al., 1995) . Whereas wild-type SHP-2, dominant-negative C/S SHP-2 (Noguchi et al., 1994) , leukemia (JMML)-specific SHP-2 (E76K or D61Y) and Noonan-specific SHP-2 (N308D) failed to transform NIH3T3 cells in the focus-formation assay (Figure 4a ), the newly isolated T507K SHP-2 mutant efficiently induced transformed NIH3T3 foci (Figures 4a  and b) . Immunoblotting analysis revealed that each of SHP-2 mutant with oncogenic RAS-like activity D Miyamoto et al the SHP-2 proteins was expressed in NIH3T3 cells at similar levels when compared 24 h after transfection (Figure 4c ). Thus, T507K SHP-2 acquired the ability to transform NIH3T3 cells in vitro.
Oncogenic potential of NIH3T3 cells expressing T507K SHP-2 To substantiate the above conclusion, we expanded NIH3T3 cells transformed by T507K SHP-2 and established two independent cell lines, NIH/T507K-1 and NIH/T507K-2, both of which exhibited swirling and refractile appearance that was indistinguishable from that of NIH3T3 cells transformed by HRAS
V12
(NIH/RAS) (Figure 5a ). In a soft agar assay, both NIH/ T507K-1 and NIH/T507K-2 cells showed anchorageindependent growth (Figure 5b ). Furthermore, subcutaneous inoculation of NIH/T507K-1, NIH/T507K-2 or NIH/RAS cells induced huge and lethal tumors in nude mice (four of four for NIH/T507K-1 cells, four of four for NIH/T507K-2 cells, four of four for NIH/RAS cells, zero of four for parental NIH3T3 cells), indicating that T507K SHP-2 conferred in vivo tumorigenicity to NIH3T3 cells. To gain some insights into the mechanism underlying transformation of NIH3T3 cells by T507K SHP-2, we investigated activation status of the RAF-ERK pathway, one of major RAS-effector pathways, in parental or transformed NIH3T3 cells. As expected, RAF1 was strongly activated in NIH/T507K-1 and NIH/T507K-2 as well as NIH/RAS cells as determined by its migration retardation on SDS-polyacrylamide gel electrophoresis (Figure 5c ). To examine if T507K SHP-2 deregulates the RAF-ERK pathway more efficiently than other SHP-2 mutants, we expressed wild-type SHP-2, leukemiaspecific SHP-2, Noonan-specific SHP-2 or T507K SHP-2 in NIH3T3 cells and investigated the levels of RAF1 activation. The results of the experiment showed that leukemia-and Noonan-associated SHP-2 mutants such as E76K and N308D are also capable of inducing strong RAF1 activation (Figure 5d ), suggesting that mutant SHP-2-mediated hyperactivation of the RAF-ERK pathway is not sufficient for the transformation of nonhematopoietic cells.
Discussion
In the present study, we identified a somatic PTPN11 mutation that gives rise to an SHP-2 mutant with T507K substitution in human solid tumor. The T507K SHP-2 mutant showed altered substrate specificity with slightly elevated basal phosphatase activity and exhibited oncogenic RAS-like transforming activity.
SHP-2 mutations are responsible for the developmental disorder Noonan syndrome that predisposes neoplasms, most notably JMML, a childhood leukemia characterized by excessive proliferation of immature myelomonocytic cells. SHP-2 mutations are also found in about 35% of patients with nonsyndromic JMML, arguing SHP-2 as the first oncoprotein with tyrosine phosphatase activity (Mohi and Neel, 2007) . Furthermore, the observation that approximately 25% of JMML cases possess oncogenic RAS mutation indicates that deregulation of the RAS-effector pathways through gain-of-function mutation of RAS or SHP-2 plays a causative role in the development of JMML (Lauchle et al., 2006) . Intriguingly, the individual amino-acid substitutions of SHP-2 identified in Noonan syndrome and sporadic JMML hardly overlap each other , and leukemia (JMML)-specific SHP-2 mutants generally exhibit highly elevated basal phosphatase activity compared with the basal phosphatase level of wild type or Noonan-specific SHP-2 (Tartaglia et al., 2003 Keilhack et al., 2005) .
The T507K SHP-2 mutant found in this work is substantially different from Noonan-specific or leukemia-specific SHP-2 mutants in that it can transform NIH3T3 both in vitro and in vivo, indicating that the mutant represents a distinct class of SHP-2 mutants. So far, no more than a dozen of SHP-2 mutations have been identified in solid tumors, and T507K mutation is the only mutation that has been identified twice from solid tumors, a neuroblastoma and a hepatocellular carcinoma Given that T507K SHP-2 exhibits altered substrate specificity, the SHP-2 mutant may dephosphorylate a set of substrates that are qualitatively and/ or quantitatively different from those dephosphorylated by wild-type SHP-2, Noonan-specific SHP-2 or leukemia-specific SHP-2. Both T507K SHP-2 and the leukemia-specific E76K SHP-2 are capable of eliciting aberrant activation of RAF1. Although constitutive activation of the RAS-RAF-ERK pathway intimately relates with NIH3T3 transformation (Mansour et al., 1994) , the failure of E76K SHP-2 to transform NIH3T3 cells indicates that aberrant activation of the RAS-RAF-ERK pathway per se is not sufficient for the transformation of NIH3T3 cells. In this regard, we also investigated the effects of wild-type SHP-2, T507K SHP-2 and E76K SHP-2 on another RAS-effector pathway, the PI3K-AKT pathway and found that none of these SHP-2 mutants significantly modifies AKT activity when expressed in NIH3T3 cells (data not shown). Accordingly, at present, the precise mechanism by which T507K SHP-2 transforms NIH3T3 cells remains obscure. Given that simple overexpression of wild-type RAS cannot transform NIH3T3 (Tabin et al., 1982) , the process of cell transformation by oncogenic RAS might utilize downstream effectors that are not employed by wild-type RAS. Activities of such oncogenic RAS-specific effectors might also be governed by neomorphic T507K but not wild type or hypermorphic SHP-2. The answer to this important question may require molecular identification of tyrosine-phosphorylated proteins that specifically associated with a substrate-trapping mutant of T507K SHP-2, which may be oncogenic substrates that must be dephosphorylated by T507K SHP-2 during transformation of non-hematological cells. Obviously, the work warrants future investigation.
The limited contribution of SHP-2 mutation in solid tumors indicates that only a small number of mutants such as T507K can confer oncogenic RAS-like transforming potential to SHP-2. It is therefore possible that alternative strategies operate to deregulate SHP-2 in the development of solid tumors. For instance, GAB2, the scaffold and activator of SHP-2, is overexpressed in a fraction of mammary carcinomas (Bentires-Alj et al., 2006) . Development of gastric carcinoma is closely associated with cagA-positive Helicobacter pylori infection. H. pylori CagA is delivered into gastric epithelial cells, where it binds to and deregulates SHP-2 (Higashi et al., 2002; Hatakeyama, 2004) . The CagA-associated/ deregulated SHP-2 might behave like T507K SHP-2 to promote gastric carcinogenesis. 
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In conclusion, the present work provides the first genetic and biochemical evidence for the presence of a distinct class of gain-of-function SHP-2 mutations that could be involved in the development of solid tumors. Our results also reveal that quantitative and/or qualitative alteration in phosphatase activity determines the transforming potential and target cell/tissue spectrum of individual SHP-2 mutants as oncoproteins.
Materials and methods

Subjects
Surgically extracted frozen tumor and corresponding nontumor tissues were obtained from the Division of Surgical Oncology, Graduate School of Medicine, Hokkaido University and its affiliated hospitals. Informed consent was obtained from all the tumor patients, and this study was approved by the Ethics Committees of the Institute for Genetic Medicine and the Graduate School of Medicine, Hokkaido University.
Plasmids
Mammalian expression vectors for SHP-2 and HRAS V12 were described previously (Higashi et al., 2004; Tsutsumi et al., 2006) . cDNAs encoding mutant SHP-2 proteins were made from PTPN11 cDNA by site-directed mutagenesis and were cloned into pSP65SRa vector. An expression vector for the substrate-trapping DM SHP-2-Myc with T507K or E76K substitution (DM/T507K SHP-2-Myc and DM/E76K SHP-2-Myc, respectively) was made from pSP65SRa/DM SHP-2-Myc. Bacterial expression vectors for glutathione-Stransferase-tagged SHP-2 were made using pGEX-6P-2 (GE Healthcare, Piscataway, NJ, USA).
Mutation analysis of PTPN11
Mutation screening was carried out by PCR-SSCP analysis (Orita et al., 1989) . PCR was performed in a reaction volume of 20 ml containing 0.1 mg genomic DNA, 1 pmol of each primer, 4 nmol dNTPs, 0.1 unit Ex Taq polymerase (TaKaRa, Shiga, Japan). Primer pairs and PCR conditions for amplification of PTPN11 exons were described previously (Kosaki et al., 2002) .
Molecular modeling
The three-dimensional structure of the basal inactive form of SHP-2 was obtained through Protein Data bank code 2SHP (Hof et al., 1998) with the use of DeepView Swiss-PdbViewer 3.7 (Guex and Peitsch, 1997) .
In vitro phosphatase assays Recombinant SHP-2 proteins were produced according to the method described previously (Keilhack et al., 1998) . In vitro phosphatase assays were conducted in 30 mmol l À1 HEPES (pH 7.4), 120 mmol l À1 NaCl, 5 mmol l À1 dithiothreitol, 10 mmol l À1 pNPP and 100 nmol l À1 purified SHP-2 proteins at 30 1C for 30 min. Dephosphorylation of pNPP was evaluated by measuring absorbance at 410 nm.
Cell culture and transfection AGS human gastric epithelial cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and transfected by using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine serum. COS-7 cells were cultured in DMEM with 10% FBS. NIH3T3 and COS-7 cells were transfected by the calcium-phosphate method.
Immunoprecipitation and immunoblotting SHP-2 substrate-trapping assay was performed as described previously (Tsutsumi et al., 2006) . In brief, AGS cells were transfected with wild type or mutant SHP-2-expressing vector and were cultured in PRMI1640 medium containing 10% FBS. Culture medium was changed at 12 h intervals and, at 36 h after transfection, cells were fed with fresh RPIM1640 containing 20% FBS and were cultured for additional 30 min before harvest. Cell lysates prepared were then subjected to immunoprecipitation with the use of an anti-Myc antibody (9E10). Total cell lysates and anti-Myc immunoprecipitates were immunoblotted with an antibody against phosphotyrosine (4G10) (Upstate, Lake Placid, NY, USA), FAK (Santa Cruz, Santa Cruz, CA, USA), Myc (9E10), HRAS (Santa Cruz), RAF1 (Santa Cruz) or Actin (Santa Cruz).
NIH3T3 transformation assays
For focus-formation assay, NIH3T3 cells (5 Â 10 5 ) in a 100-mm dish were transfected with 20 mg of DNA. After 12 h, the cells were reseeded and cultured for 3 weeks in DMEM with 5% bovine serum. The cells were then fixed with formalin and stained with 1% crystal violet. For soft agar colony formation assay, 1 Â 10 4 cells in 1.5 ml of DMEM containing 10% bovine serum and 0.33% Bacto-Agar (DIFCO, Detroit, MI, USA) were seeded onto the solidified bottom layer of 7 ml of DMEM containing 10% bovine serum and 0.5% agar. The plates were photographed after 2 weeks. For in vivo xenograft assay, 6-weeks-old female athymic BALB/cAJc1-nu/nu mice were injected subcutaneously with 1 Â 10 6 cells in 0.1 ml of PBS. All mice were maintained in the animal facility of the Institute for Genetic Medicine, Hokkaido University and treated according to the Laboratory Animal Control Guidelines of our institute, which conform to those of the National Institute of Health American Association of Laboratory Animal Control.
